Why Glucosamine Doesn't Work for Horses — And What Actually Does
Share
Why NDS Does Not Use Glucosamine in Its Horse Joint Supplements
Glucosamine is found in the majority of equine joint supplements on the market. Independent pharmacokinetic research shows its oral bioavailability in horses is less than 6%. Here is what that means for your horse, and why NDS takes a different approach.
If you have ever bought a joint supplement for your horse, the chances are glucosamine was the primary active ingredient. It has dominated the equine joint supplement market for decades, borrowing its popularity largely from the human supplement industry where it became a household name in the 1990s.
The problem is that horses are not humans. Their digestive systems work in a fundamentally different way, and the research into how glucosamine behaves once it enters the equine gut paints a picture that most supplement brands prefer not to discuss openly.
At NDS, we do not use glucosamine in any of our equine joint formulations. This article explains the science behind that decision.
How the horse's digestive system changes everything
Horses are hindgut fermenters. Unlike humans, who digest most nutrients in the small intestine through enzymatic processes, horses rely heavily on microbial fermentation in the large intestine and caecum to break down feed. This has significant implications for any orally administered supplement.
Glucosamine is an amino sugar. When it enters the equine hindgut, it becomes available to the vast microbial population that drives fermentation. A substantial proportion of the glucosamine dose is metabolised by gut bacteria before it has any opportunity to be absorbed into the bloodstream. What makes it through to systemic circulation is a fraction of what was fed, and the research has measured exactly how small that fraction is.
The hindgut fermentation problem in plain terms: feeding glucosamine to a horse is not the same as administering it intravenously or even orally in a simple-stomached species. The equine gut environment actively reduces how much reaches the blood, and therefore how much ever reaches the joint.
What the pharmacokinetic research shows
Two independent pharmacokinetic studies have specifically measured the oral bioavailability of glucosamine in horses at clinically relevant doses. Their findings are consistent and clinically important.
In the Laverty study, eight horses received glucosamine hydrochloride at 20mg per kg of bodyweight, a dose typical of commercial equine joint supplements. Blood samples were collected over 12 hours and synovial fluid was sampled at 0, 1, and 12 hours after dosing.
The finding: mean apparent oral bioavailability of glucosamine hydrochloride in horses was 5.9%, with high variability between individual horses. Synovial fluid concentrations were measured at each timepoint.
A separate comparison study found that even glucosamine sulfate, the better-absorbed form, achieved only 9.4% oral bioavailability in horses compared to 44% in humans. The HCl form achieved just 6.1%.
Mississippi State University Extension Service, reviewing this research, concluded that oral glucosamine dosing resulted in serum and synovial fluid concentrations too low to modify joint cell activity, and that joint tissue cells used the extra glucosamine slowly or not at all.
To put those numbers in practical terms: if you feed your horse 10 grams of glucosamine, independent research suggests approximately 600mg enters circulation. Of that, the proportion that reaches the synovial fluid of multiple large joints under mechanical load is smaller still. Whether any clinically meaningful concentration is achieved at the cartilage level is, based on current evidence, questionable.
The label accuracy problem
The poor bioavailability picture is compounded by a separate issue: label accuracy in commercial equine joint supplements.
A study evaluating glucosamine levels in 23 commercial equine oral joint supplements found that based on the glucosamine amounts actually measured, a 10g dose would have been achieved by only 2 of the 23 products tested. Fourteen of the 23 products were considered adequate in terms of the amount of glucosamine present compared to label claims. The remaining products contained less glucosamine than stated.
This matters because the doses used in positive human glucosamine trials were already at the threshold of clinical significance. In horses, where bioavailability is a fraction of what it is in humans, starting from a lower actual dose than the label claims makes the likelihood of any therapeutic effect even more remote.
Equine gut bacteria metabolise glucosamine before absorption, dramatically reducing how much reaches the bloodstream compared to simple-stomached species.
Multiple independent pharmacokinetic studies confirm less than 6% of an oral glucosamine dose in horses reaches systemic circulation at standard supplementation doses.
Researchers found concentrations in synovial fluid too low to modify joint cell activity, meaning the supplement is unlikely to reach the tissue it is intended to support.
An evaluation of 23 commercial equine joint supplements found only 2 delivered a 10g dose based on actual content measured. Many contained less glucosamine than their label claimed.
Even if absorbed, glucosamine only provides substrate. It does not signal chondroblasts to initiate cartilage repair, which is the mechanism that produces meaningful tissue-level outcomes.
A 2014 study supplementing aged horses with a joint supplement mix including glucosamine found no improvement in stride length compared to placebo.
The signalling problem: even if it reached the joint
There is a further issue that applies regardless of the absorption question. Glucosamine is a substrate: it provides raw material that can theoretically be incorporated into cartilage matrix. What it does not do is signal the chondroblasts responsible for cartilage repair to become more active.
Think of it this way. Cartilage repair requires two things: a signal to the cells responsible for building the matrix, telling them to increase their activity, and the raw materials to build with once those cells have been activated. Glucosamine only ever offers the second half of that equation. The first half, the biological signal, is absent.
NDS tissue-specific collagen peptides work on both fronts simultaneously. Approximately 10% of the CPF 218 peptide is absorbed intact and travels directly to connective tissue, where it binds to receptors in chondroblasts and emits the repair signal. The remaining 90% is broken down into proline, glycine, and hydroxyproline, the precise amino acids that form the collagen matrix of cartilage, and these are delivered directly to the tissue that has just been signalled to rebuild.
Why NDS Equine uses CPF 218 instead of glucosamine:
- 10% absorbed intact, binds to receptors in chondroblasts and signals active connective tissue repair in tendons, ligaments, and cartilage
- 90% broken down into proline, glycine, and hydroxyproline, the precise amino acids that form the collagen matrix of equine connective tissue, delivered directly to the stimulated tissue
- 98.4% digestibility, meaning almost nothing is lost in the digestive process regardless of gut type, including the hindgut fermentation environment of the horse
- The same dual-action mechanism documented in human clinical research applies to equine connective tissue, signal and substrate working together
- Ingredients tested for FEI banned substances, suitable for competition horses across all disciplines
"The pharmacokinetic data on glucosamine in horses is not ambiguous. Less than 6% reaches circulation at standard doses, and the synovial fluid concentrations measured in research are below the threshold for modifying joint cell activity. We formulate from the biology, not from the shelf."
NDS Clinical Advisory, Equine Nutrition
What this means for your horse
If your horse is currently on a glucosamine-based joint supplement, this research does not necessarily mean you should stop immediately without veterinary guidance. What it does mean is that the active ingredient you are paying for may not be reaching the tissue you are trying to support in any clinically meaningful quantity.
The equine joint supplement market has not kept pace with the pharmacokinetic research. Many products continue to lead with glucosamine because it is a recognised name, not because the evidence in horses supports it as a primary active ingredient at oral doses.
A supplement that works with equine physiology rather than against it starts from a different place entirely: an ingredient with documented digestibility, a defined molecular weight, a clear absorption profile, and a biological mechanism that does not depend on overcoming 94% gut losses to reach the tissue that needs support.
Frequently asked questions
My horse has been on glucosamine for years and seems better. Could it still be working?
There are several explanations for perceived improvement that do not require glucosamine to be reaching the joint in meaningful quantities. Other ingredients in combination products, changes in management, natural variation in symptoms, and placebo effect on the owner's observation of their horse are all factors. The pharmacokinetic evidence does not mean no horse on glucosamine has ever improved, it means the improvement is unlikely to be attributable to glucosamine reaching the cartilage in a therapeutically meaningful concentration.
Is glucosamine sulfate better than glucosamine HCl for horses?
Marginally. Research found glucosamine sulfate achieved 9.4% oral bioavailability in horses compared to 6.1% for the HCl form. Both are substantially lower than the 44% bioavailability documented for glucosamine sulfate in humans. Even the better-absorbed equine form delivers a fraction of what reaches circulation in a human taking the same supplement.
Why do so many equine supplements still use glucosamine?
Market convention and consumer recognition. Glucosamine became the dominant joint supplement ingredient for humans in the 1990s, and equine supplement brands largely adopted it without adequately accounting for the fundamental differences in equine digestive physiology. The pharmacokinetic research questioning its oral bioavailability in horses has not yet widely reached horse owners, despite having been published in peer-reviewed veterinary literature since 2004.
What does NDS use in its equine joint supplements instead?
CPF 218, a tissue-specific bioactive collagen peptide formulated to target chondroblasts in cartilage, tendons, and ligaments. With 98.4% digestibility, the majority of the active compound survives the digestive process regardless of gut type. It works on two fronts simultaneously: 10% signals cartilage-building cells to initiate repair, and 90% supplies the specific amino acids those cells need as building material. Ingredients are tested for FEI banned substances.
NDS Equine Ezy Move uses CPF 218, a tissue-specific collagen peptide with 98.4% digestibility and documented connective tissue repair mechanisms. No glucosamine. No compromises on bioavailability.
Explore NDS Equine Range →Sources: Du et al. (2004), Equine Veterinary Journal; Laverty et al. (2005), Osteoarthritis and Cartilage; Osteoarthritis and Cartilage (2008), glucosamine sulfate vs HCl comparison in horses; Evaluation of glucosamine levels in commercial equine oral supplements (2006); Mississippi State University Extension Service, Equine Joint Supplementation review; Mad Barn independent glucosamine review (2022); Lydeking E. (2020), NDS Collagen clinical white paper.